Navigation Links
Insmed's ARIKACE® Demonstrates Sustained Benefit Through Six Cycles of Treatment for Cystic Fibrosis Patients With Pseudomonas Lung Infections
Date:6/10/2011

consistent results of improved lung function throughout all six cycles of this study," said Professor Minic.  "In addition, there were no unexpected adverse events associated with the longer term use of the drug.  Taken as a whole, these data indicate that ARIKACE has the potential, if approved, to be an important product for CF patients with Pseudomonas lung infections."  

ARIKACE also demonstrated statistically significant reduction from baseline in Pseudomonas aeruginosa density, including mucoid strains, which was sustained during the treatment and off-treatment periods of the six cycles.  The estimated change from baseline in Log10 CFU over time was -0.6 log (95% CI, -0.2 to -0.9 log; p=0.0030).  Mucoid strains of Pseudomonas are often difficult to suppress with antibiotics and play a significant role in progression of CF lung disease.  In addition, there was no significant shift in the minimum inhibitory concentration (MIC90) of ARIKACE against Pseudomonas over the course of the six cycles, which suggests a lack of resistance development during the study period.

"These results further strengthen the clinical data package Insmed is developing for ARIKACE in the treatment of CF patients," said Renu Gupta, M.D., Executive Vice President Development & Chief Medical Officer of Insmed.  "The data are also indicative of why we are so excited to begin our Phase 3 clinical program in the CF indication, which we expect to initiate in the second half of this year.  For potential registration of ARIKACE in the U.S., we intend to conduct a placebo-controlled clinical trial, and for European registration, we intend to conduct a trial that compares ARIKACE to Novartis Corporation's TOBI®.  Results from these studies are anticipated in the first half of 2013."

"We are pleased that the development of ARIKACE continues to proceed expeditiously," said Robert J.
'/>"/>

SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Precision Therapeutics Demonstrates Utility of Multi-Gene Predictors in Predicting Chemotherapy Response for Breast Cancer Patients
2. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
3. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
4. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
5. VivaGel(R) Demonstrates Efficacy in Bacterial Vaginosis
6. PROMUS Element™ Stent Demonstrates Exceptional Safety and Effectiveness in PLATINUM Small Vessel Study
7. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
8. HERCULES Trial Demonstrates Significant Reduction in Systolic Blood Pressure While Revealing Marker in Hypertensive Patients Does Not Predict Outcomes of Renal Artery Stenting
9. SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease
10. Baxa Corporation Demonstrates End-to-End Environmental Stewardship
11. REMEDIAL II Trial of PLCs RenalGuard® Demonstrates Greater Efficacy than Current Standard of Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... SOUTH EASTON, Mass. , Sept. 19, 2014 ... the "Company") today announced it has received and ... throughput Barozyme HT48 instruments and has begun to ... believes the first instrument will be ready for ... will be built and released at a rate ...
(Date:9/19/2014)... , September 19, 2014 ... IQ den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt ... interaktive PDF, verfügbar unter pharmaserialisation.com , zeigt ... sie jeweils in Kraft treten. Für ... nicht länger um das "ob", sondern darum, "wann" ...
(Date:9/19/2014)... CAMBRIDGE, Mass. , Sept. 19, 2014 ... a provider of advanced cancer genome analysis and ... leader in discovering and developing highly selective kinase ... first-ever comprehensive genomic study of malignant mixed Mullerian ... the female reproductive system, also known as carcinosarcoma. ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... Delivers Unprecedented Specificity for ... Diagnosing ... Medical Solutions,Diagnostics (http://www.siemens.com/diagnostics ) announced that it has ... rights to develop an,automated stimulating TSH receptor antibody (TRAb) ...
... more effective than,tamoxifen at preventing breast cancer recurrence ... with hormone-responsive cancers. In addition, the increased,risk of ... being treated with,anastrozole disappears after treatment ends., ... Antonio Breast Cancer,Symposium, Professor John Forbes of the ...
Cached Medicine Technology:Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu 2Siemens Medical Solutions Diagnostics Inks Agreement with KreLo Medical Diagnostics to Expand Thyroid Immunoassay Menu 3Anastrozole Confirmed Superior in Breast Cancer Prevention 2
(Date:9/21/2014)... “Cluster headaches are sometimes called ‘Suicide Headaches’ because ... said Steve Young of Ew Publishing; “I’ve had cluster ... is more intense.” , “It should be a relief ... that medical research is pointing to some relief and ... Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous biochemical found in ...
(Date:9/21/2014)... According to latest National Vital Statistics Reports ... (10.5 births per 1,000 women in 2013). Since 2000, the ... by 2 percent per year. The birth rate for women ... over) also rose, the first such increase since 2008. Ultimately ... as many first births to women aged 35 and older ...
(Date:9/20/2014)... 2014 Weight Destroyer , a ... expert Michael Wren that has already helped tens of ... health conditions like high blood pressure, high cholesterol, and ... prompting an investigative review. , “Weight Destroyer is ... down by showing people what is truly effective when ...
(Date:9/20/2014)... 2014 Increases in household, construction ... waste treatment volumes. However, government regulations and higher ... landfill. According to IBISWorld industry analyst Alen Allday, ... aimed at reducing the volume of waste generated, ... recovered.” Still, a large proportion of waste generated ...
(Date:9/20/2014)... The print component of “Work-Life ... the Calgary Herald, with a circulation of approximately ... The digital component is distributed nationally through a ... of top news sites and partner outlets. To ... http://www.worklifebalanceinfo.ca . , The publication features an ...
Breaking Medicine News(10 mins):Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 2Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 3Health News:Statistics Reveal That the Number of 'Older' First-Time Mothers Is Growing 4Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Waste Treatment and Disposal Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2
... , , , , ... action suit involving drug wholesaler McKesson Corporation and data publishers First Data Bank ... terms, according to Greg Ruc i nski , ... a leading next-generation health information business. , , "There,s ...
... NASHVILLE, Tenn., Aug. 11 Emdeon Inc. (the "Company") today ... of its Class A common stock at a price of $15.50 ... the Company and 12,975,000 were offered by selling stockholders. The shares ... ticker symbol "EM." To the extent that the underwriters sell more ...
... Study reiterates that young are most vulnerable , TUESDAY, Aug. ... is doing its part to make sure that doctors and ... link between antidepressant use and suicide, which indicate that the ... trials involving nearly 100,000 people who took antidepressants showed that ...
... , WEST PALM BEACH, Fla., Aug. 11 ... he a ring aids and hearing care announced ... designed exclusively for AARP members. The program is scheduled to be made available ... be extended to AARP members in all 50 states and the U.S. territories. ...
... , Dr. Mubin Syed evaluates findings; calls ... Aug. 11 A new study by Mayo Clinic researchers has ... vertebroplasty to treat osteoporotic spinal fractures. , , ... injected into vertebrae to relieve pain and improve mobility in patients ...
... , , Survey seeks ... , , CHICAGO, Aug. 11 Participate in ... to/publicsurvey and become eligible to win a $150 Amazon.com ... ADA.org. , , ADA.org provides news and information on hundreds ...
Cached Medicine News:Health News:Confusing New PBM Drug Pricing Terms Leave Payors Unsure of Next Steps 2Health News:Confusing New PBM Drug Pricing Terms Leave Payors Unsure of Next Steps 3Health News:Confusing New PBM Drug Pricing Terms Leave Payors Unsure of Next Steps 4Health News:Confusing New PBM Drug Pricing Terms Leave Payors Unsure of Next Steps 5Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 2Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 3Health News:Emdeon Inc. Prices Initial Public Offering of Class A Common Stock at $15.50 Per Share 4Health News:Suicide Risk With Antidepressants Falls With Age 2Health News:Suicide Risk With Antidepressants Falls With Age 3Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 2Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 3Health News:HearUSA Makes Hearing Aids and Care Available to AARP Members 4Health News:Noted Vertebroplasty Expert Cites Concerns About Recently Published Study 2Health News:American Dental Association Web Survey Offers Chance at $150 Gift Certificate 2
... The advanced performance benefits of TiMAX™ ... generation of implants. DePuy ACEs Large Fragment ... biocompatibility and enhanced imaging compatibility over traditional ... unique thread design in the TiMAX bone ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
... Fragment System has been conceived and engineered ... and user-friendly instrumentation. The modular system of ... instrumentation is designed to provide the surgeon ... and classic techniques of open reduction and ...
Medicine Products: